Castle Biosciences
NASDAQ: CSTLFriendswood, US · 3 known investors
Castle Biosciences develops, manufactures and commercializes diagnostic and prognostic molecular tests in areas such as dermatology (melanoma), uveal melanoma, gastroenterology (Barrett's esophagus) and mental health. The company operates as a multi-site diagnostics provider serving clinicians and patients across the United States.
BiotechDigital HealthHealthtechMedical Devices
Founders & leadership
DM
Derek MaetzoldCo-founder
DJ
Derek J. MaetzoldFounder, President & Chief Executive Officer
FS
Frank StokesChief Financial Officer
KO
Kristen OelschlagerChief Operating Officer
TJ
Toby JuvenalChief Commercial Officer
HC
Hillary CarusoChief of Staff
JC
Joe Cook, Jr.Named on SEC filing
Board
MA
Mara AspinallBoard director
DB
Daniel BradburyBoard director
JC
Joseph Cook, Jr.Board director
GK
Garheng KongBoard director
BA
Bonnie AndersonBoard director
Investors · 3
Reported raises · per SEC filings
Form D private placements$54M disclosed across 8 rounds · 2011–2019
▶$10MraisedJul 2019 · 1 investors · BiotechnologyRule 506(b)
▶$10MraisedJul 2019 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Derek MaetzoldExecutive Officer, Director
- Mara AspinallDirector
- Bonnie AndersonDirector
- Daniel M. BradburyDirector
- Joseph C. Cook, IIIDirector
- David Kabakoff, Ph.D.Director
- Frank StokesExecutive Officer
- Bernhard E. SpiessExecutive Officer
- Federico Monzon, M.D., FCAPExecutive Officer
- G. Bradley ColeDirector
- Offering amount
- $20M
- Amount sold
- $10M
- First sale
- Jul 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$11.8MraisedMar 2019 · 65 investors · BiotechnologyRule 506(b)
▶$11.8MraisedMar 2019 · 65 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Federico Monzon, M.D., FCAPExecutive Officer
- Mara AspinallDirector
- G. Bradley ColeDirector
- Joseph C. Cook, Jr.Director
- Derek MaetzoldExecutive Officer, Director
- Daniel M. BradburyDirector
- Bernhard E. SpiessExecutive Officer
- Frank StokesExecutive Officer
- Bonnie AndersonDirector
- David Kabakoff, Ph.D.Director
- Offering amount
- $11.8M
- Amount sold
- $11.8M
- First sale
- Jan 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$5.1MraisedJun 2018 · 44 investors · BiotechnologyRule 506(b)
▶$5.1MraisedJun 2018 · 44 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Federico Monzon, M.D., FCAPExecutive Officer
- Bernhard E. SpiessExecutive Officer
- Bonnie AndersonDirector
- Mara AspinallDirector
- Joseph C. Cook, Jr.Director
- Derek MaetzoldExecutive Officer, Director
- Daniel M. BradburyDirector
- Frank StokesExecutive Officer
- David Kabakoff, Ph.D.Director
- Offering amount
- $5.3M
- Amount sold
- $5.1M
- First sale
- May 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$5.5MraisedJan 2018 · 48 investors · BiotechnologyRule 506(b)
▶$5.5MraisedJan 2018 · 48 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Derek MaetzoldExecutive Officer, Director
- Frank StokesExecutive Officer
- David Kabakoff, Ph.D.Director
- Joseph C. Cook, Jr.Director
- Federico Monzon, M.D., FCAPExecutive Officer
- Bonnie AndersonDirector
- Daniel M. BradburyDirector
- Bernhard E. SpiessExecutive Officer
- Mara AspinallDirector
- Offering amount
- $5.5M
- Amount sold
- $5.5M
- First sale
- Jan 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$11.7MraisedJul 2015 · 17 investors · BiotechnologyRule 506(b)
▶$11.7MraisedJul 2015 · 17 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Mara AspinallDirector
- Daniel BradburyDirector
- Joseph Cook, Jr.Director
- Garheng KongDirector
- Bonnie AndersonDirector
- Derek MaetzoldExecutive Officer, Director
- Offering amount
- $20M
- Amount sold
- $11.7M
- First sale
- Jul 2015
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$7.5MraisedAug 2014 · 4 investors · BiotechnologyRule 506(b)
▶$7.5MraisedAug 2014 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Joe Cook, Jr.Director
- Derek MaetzoldExecutive Officer, Director
- Daniel BradburyDirector
- Offering amount
- $12M
- Amount sold
- $7.5M
- First sale
- Aug 2014
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.5MraisedAug 2014 · 4 investors · BiotechnologyRule 506(b)
▶$1.5MraisedAug 2014 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Daniel BradburyDirector
- Joe Cook, Jr.Director
- Derek MaetzoldExecutive Officer, Director
- Offering amount
- $1.5M
- Amount sold
- $1.5M
- First sale
- Sep 2011
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1MraisedMay 2014 · 3 investors · BiotechnologyRule 506(b)
▶$1MraisedMay 2014 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Joe Cook, Jr.Director
- Daniel BradburyDirector
- Derek MaetzoldExecutive Officer, Director
- Offering amount
- $1M
- Amount sold
- $1M
- First sale
- Apr 2014
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 3
by search overlapAmerican Cancer Society (ACS)235 shared keywordsThe American Cancer Society is a nonprofit cancer-fighting organization that combats cancer through advocacy, research, and patient support. It provides information, guidance, caregiver resources, screening guidance, and clinical trial navigation for cancer patients, families, and caregivers, and funds cancer research.
Medscape226 shared keywordsMedscape is an online medical information platform providing clinical news, expert perspectives, case studies, quizzes, and reference material across specialties such as cardiology, oncology, neurology, and psychiatry. It serves physicians, nurses, pharmacists, residents, and medical students.
Cancerresearchuk224 shared keywordsCancer Research UK funds research across discovery, detection, prevention and treatment of cancer to improve patient outcomes and extend survival. It operates as a research funder and scientific organization serving academic and clinical researchers.
Companies competing with Castle Biosciences for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Castle Biosciences do?
- Castle Biosciences develops, manufactures and commercializes diagnostic and prognostic molecular tests in areas such as dermatology (melanoma), uveal melanoma, gastroenterology (Barrett's esophagus) and mental health. The company operates as a multi-site diagnostics provider serving clinicians and patients across the United States.
- Who founded Castle Biosciences?
- Castle Biosciences was founded by Derek Maetzold, Derek J. Maetzold.
- Who are Castle Biosciences's investors?
- Castle Biosciences's investors include BioBrit, Illumina Ventures, Mountain Group Capital.
- How much funding has Castle Biosciences raised?
- Castle Biosciences has disclosed $54M raised across 8 rounds.
- Where is Castle Biosciences headquartered?
- Castle Biosciences is headquartered in Friendswood, US.